Can Ozempic Help with Diabetes? Clinical Evidence & Personaliz...

Last reviewed: May 18, 2026

Last updated: May 18, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, Ozempic (semaglutide) is an FDA-approved GLP-1 receptor agonist that helps many patients with type 2 diabetes lower blood sugar levels and lose weight. Clinical trials show HbA1c reductions of 1.5–2% and weight loss averaging 5–10% over 24 weeks, depending on dose and individual factors.

For patients evaluating diabetes treatment, understanding how your body's genetic and biomarker profile may influence GLP-1 response is increasingly important. PlexusDx supports precision wellness by offering insights into peptide pathway predispositions, helping you and your provider make more informed decisions about which GLP-1 option—branded or compounded—may align with your health goals.

How Ozempic and Other GLP-1 Agonists Work in Diabetes

GLP-1 receptor agonists mimic the glucagon-like peptide-1 hormone, which regulates blood sugar by stimulating insulin release when glucose is high. They also slow stomach emptying and reduce hunger signals, contributing to both glycemic control and weight reduction in type 2 diabetes management.

Ozempic is injected once weekly and is distinct from other GLP-1 options like Saxenda (liraglutide, daily injection) or oral semaglutide (Rybelsus). Each formulation has different pharmacokinetics and dosing schedules, which may influence tolerability and efficacy in individual patients.

Clinical Evidence and Real-World Efficacy Outcomes

Multiple randomized controlled trials confirm GLP-1 agonists reduce HbA1c, fasting glucose, and cardiovascular events in type 2 diabetes. The SUSTAIN trials demonstrated Ozempic's superiority over comparator drugs in glucose control and weight loss across baseline HbA1c levels and comorbidities.

Clinical Outcome	Typical Range / Key Finding
HbA1c Reduction	1.5–2.0% (week 24–30 studies)
Weight Loss Average	5–10% of baseline body weight
Blood Pressure Reduction	2–4 mmHg systolic decrease
Cardiovascular Events	26% reduction in major adverse cardiac events (SUSTAIN-6)

Biomarkers and Genetic Factors That May Influence GLP-1 Response

Individual response to GLP-1 therapy varies based on baseline metabolic state, insulin secretion capacity, and genetic predispositions in GLP-1 signaling pathways. Biomarkers such as C-peptide levels, proinsulin-to-insulin ratio, and inflammatory markers (CRP, IL-6) may provide context for expected treatment response.

Genetic variants in key peptide-pathway genes—such as GLP1R rs6923761, GIPR rs1800437, and MC4R rs17782313—are associated with differences in appetite regulation, glucose metabolism, and weight loss response. These predispositions don't determine exact outcomes but may help guide personalized treatment conversations with your provider.

Safety Considerations and Who Should Use GLP-1 Therapy

GLP-1 agonists are contraindicated in personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Common side effects include nausea, vomiting, diarrhea, and constipation, typically mild and transient. Dehydration and pancreatitis are rare but serious risks requiring immediate medical attention.

GLP-1 therapy is indicated for type 2 diabetes management and weight loss in patients with obesity or overweight and comorbidities. Patients with type 1 diabetes, severe renal impairment, or acute illness should consult providers before initiation. Dose titration schedules and monitoring frequency vary by individual risk profile and treatment goals.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context by identifying your genetic predispositions in GLP-1 and GIP receptor pathways, as well as appetite and energy-metabolism genes. This information, interpreted with a qualified healthcare provider, can support more informed discussions about whether GLP-1 therapy aligns with your metabolic profile and treatment goals.

The test reveals variants such as GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—all associated with differences in peptide signaling, appetite response, and weight-loss predispositions. These are predispositions in genetic pathways, not predictors of exact medication response, and should be interpreted in the context of your overall clinical picture.

If you and your provider determine that GLP-1 therapy is appropriate for your diabetes or metabolic health, PlexusDx offers compounded semaglutide and tirzepatide injections from licensed 503A pharmacies at competitive prices. Genetic insights can support a more personalized conversation about formulation, dose, and monitoring strategy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.